A first-in-human clinical trial of a novel drug targeting cancer cell metabolism has shown encouraging results in patients with relapsed mesothelioma, a rare and aggressive cancer with few treatment options. The therapy works by disabling a key mitochondrial antioxidant enzyme, overwhelming tumor cells with oxidative stress while sparing healthy tissue. In the phase 1 trial, disease was controlled in 67% of patients, the drug was well tolerated, and overall survival exceeded expectations for this heavily pretreated population. The findings suggest a promising new therapeutic strategy for mesothelioma and potentially other cancers driven by the same metabolic vulnerability.

Los Angeles, CA, July 14, 2026. More than 100,000 people in the United States are waiting for a lifesaving organ transplant. For patients in need of a liver transplant, determining whether a donor liver is healthy enough to transplant is a critical part of the process.

Natural plant compounds known as polyphenols, found in berries, tea, cocoa, coffee, and extra virgin olive oil, may positively influence biological processes linked to Alzheimer’s disease and other disorders characterized by the gradual loss of nerve cells, according to a review by researchers at Semmelweis University. The analysis, published in Nutrients, suggests that these bioactive compounds may contribute to healthy brain aging.

Prostate cancer is one of the most common cancers affecting men worldwide. However, planning personalized radiotherapy in the advanced stages of the disease still requires more precise tools. Researchers at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) have now tested a novel approach. A combination of two diagnostic imaging techniques could pave the way for personalized radiotherapy. The results of the study, funded by the Wilhelm Sander Foundation, have been published in the Journal of Medicinal Chemistry (DOI: 10.1021/acs.jmedchem.6c00161).

Researchers tracked longitudinal alterations in adipose and muscle tissue through routine CT scans. Worsening visceral fat tissue degeneration predicts complications for compensated chronic hepatitis B-related cirrhosis, while sustained muscle loss signals risk in decompensated patients.